Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis.
Bottom Line: Clonal heterogeneity in lymphoid malignancies has been recently reported in adult T-cell lymphoma/leukemia, peripheral T-cell lymphoma, not otherwise specified, and mantle cell lymphoma.Survival analysis revealed that mantle cell lymphoma and diffuse large B-cell lymphoma with clonal heterogeneity showed significantly poorer prognosis, and that clonal heterogeneity was confirmed as an independent predictor of poor prognosis for both types of lymphoma.Interestingly, 8q24.1 (MYC) gain, 9p21.3 (CDKN2A/2B) loss and 17p13 (TP53, ATP1B2, SAT2, SHBG) loss were recurrent genomic lesions among various types of lymphoma with clonal heterogeneity, suggesting at least in part that alterations of these genes may play a role in clonal heterogeneity.
Affiliation: Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan.Show MeSH
Related in: MedlinePlus
Mentions: Chromosomal regions and frequencies of CNA were compared between cases with and without clonal heterogeneity (Fig. 2, Fig. S2–7; Table 3). Recurrent CNA among various types of lymphoma with clonal heterogeneity were found to be 8q24.1 (minimal overlapping lesion: MYC) gain, 9p21.3 (CDKN2A/2B) loss and 17p13 (TP53, ATP1B2, SAT2, SHBG) loss. The 8p24.1 (MYC) gain was found in significantly more cases with clonal heterogeneity than in those without clonal heterogeneity in follicular lymphoma and PTCL-NOS. The 9p21.3 loss was found in mantle cell lymphoma, DLBCL and PTCL-NOS. The 17p13 loss was found in mantle cell lymphoma, DLBCL, Burkitt lymphoma and PTCL-NOS (Fig. 3).
Affiliation: Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan.